Dr. George on the Importance of the DESTINY-Breast04 Trial in HER2-Low Breast Cancer

In Partnership With:

Partner | Cancer Centers | <b>RWJBarnabas Health and Rutgers Cancer Institute of New Jersey</b>

Mridula George, MD, discusses the clinical implications of the phase 3 DESTINY-Breast04 trial in breast cancer.

Mridula George, MD, medical oncologist, Stacy Goldstein Breast Cancer Center, Rutgers Cancer Institute of New Jersey, assistant professor of medicine, Rutgers Robert Wood Johnson Medical School, discusses the clinical implications of the phase 3 DESTINY-Breast04 trial (NCT03734029) in breast cancer. 

DESTINY-Breast04 evaluated fam-trastuzumab deruxtecan-nxki (Enhertu) vs physician’s choice of chemotherapy in patients with HER2-low metastatic breast cancer. Updated data from the trial were presented at the 2022 ASCO Annual meeting.

The DESTINY-Breast04 trial is one of the first positive studies in the HER2-low subgroup, George says. Prior clinical trials examining other HER2-targeted therapies have failed to generate a statistically significant benefit in efficacy for patients with HER2-low metastatic breast cancer, George says.

In DESTINY-Breast04’s first interim analysis, the key primary end points of progression-free survival (PFS) among patients with hormone receptor–positive, HER2-low breast cancer, and PFS in all enrolled patients, were met, George explains. Overall survival benefits were also observed, irrespective of HR status, George concludes.

Sponsored in part by Daiichi Sankyo. Content independently developed by OncLive®